뎅기열 검사 시장 보고서 : 검사 유형별, 최종사용자, 지역별(2026-2034년)

The global dengue testing market size reached USD 637.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 929.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2026-2034. The market is primarily driven by the increasing dengue fever prevalence worldwide, advancements in diagnostic technologies, rising public health awareness, and government initiatives and funding in endemic regions across the globe.

Dengue, also known as breakbone fever, is a viral infection that spreads through the bite of an infected Aedes aegypti mosquito. It causes ache in the joints and muscles, high fever, abdominal pain, vomiting, difficulty in breathing, clammy and cold skin, headache, pain behind the eyes, fatigue, rashes, and mild bleeding in the nose and gums. It is diagnosed via dengue testing, which includes enzyme-linked immunosorbent assay (ELISA), RT-PCR, and dengue IgG/IgM rapid tests. Dengue testing is performed by medical professionals using a blood sample to identify the different serotypes of the dengue virus.

Dengue Testing Market Trends:

The growing cases of dengue on account of the rising global warming and breeding sites of mosquitos across the globe represents one of the major factors driving the market. Moreover, accurate and efficient diagnosis of dengue plays a pivotal role in clinical care. It assists in pathogenesis, clinical trials, outbreak control, academic research, vaccine development, surveillance activities, early detection of severe cases, and case confirmation and differential diagnosis with other infectious diseases. These benefits are positively influencing the demand for dengue testing around the world. Besides this, densely populated areas worldwide are more disease-prone due to low living conditions. This, along with poor sanitation and waste management techniques due to lack of public awareness, is stimulating the growth of the market. In addition, healthcare professionals are encouraging people to prevent dengue by self-protection and thermal fogging of insecticides. This, coupled with awareness campaigns organized by the government of several countries, is propelling the growth of the market. Other growth-inducing factors are rapid urbanization and technological advancements in the healthcare industry. Furthermore, key market players are extensively investing in research and development (R&D) activities to develop highly efficient and cost-effective dengue test kits.

Market Segmentation:

This report provides an analysis of the key trends in each sub-segment of the global dengue testing market report, along with forecasts at the global, regional and country levels from 2026-2034. The report categorizes the market based on test type and end user.

Breakup by Test Type:

• ELISA-based Tests
• RT-PCR based Tests
• Dengue IgG/IgM Rapid Test
• Others

Breakup by End User:

• Hospitals
• Diagnostic Centers
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

1. How big is the dengue testing market?

2. What is the expected growth rate of the global dengue testing market during 2026-2034?

3. What are the key factors driving the global dengue testing market?

4. What has been the impact of COVID-19 on the global dengue testing market?

5. What is the breakup of the global dengue testing market based on the test type?

6. What is the breakup of the global dengue testing market based on the end user?

7. What are the key regions in the global dengue testing market?

8. Who are the key players/companies in the global dengue testing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Dengue Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Test Type

• 6.1 ELISA-based Tests
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 RT-PCR based Tests
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Dengue IgG/IgM Rapid Test
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Diagnostic Centers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Abnova Corporation
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
  • 13.3.3 CerTest Biotec S.L.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 DiaSorin S.p.A.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 F. Hoffmann-La Roche AG
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 InBios International Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
  • 13.3.7 NovaTec Immundiagnostica GmbH
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 OriGene Technologies Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 PerkinElmer Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Quest Diagnostics Incorporated
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Thermo Fisher Scientific Inc.
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis